
AI-Enabled Cancer Care: PharosAI | Bryden Wood Podcast
Developing a cancer drug is one of the most expensive, slow, and failure-prone processes in modern science. PharosAI is trying to change that – by building multimodal, AI-ready datasets from donated cancer tissue samples and making them available to researchers, biotech companies, and clinicians.In this episode, Technical Director Adrian La Porta speaks with PharosAI's Dr Lucie Burgess (COO) and Dr Emma Colliver (Research Fellow) about what it takes to curate cancer data at scale, why federated learning matters for patient privacy, where AI is already transforming diagnostics, and what synthetic patients could mean for clinical trials.Whether you work in life sciences, pharma manufacturing, digital health, or clinical data governance, understanding how AI is reshaping the drug discovery pipeline has direct implications for how and when new facilities will need to be built. This one is worth your time.Topics covered:00:00 Introduction00:01 What is PharosAI?00:06 Why AI can fundamentally change cancer care00:08 The venture behind the mission00:12 Lowering the barrier for UK biotech00:16 Are we at an inflection point?00:20 AI in diagnostics – what's already working00:24 Misconceptions about AI in biotech00:30 Data – acquiring, cleaning, and structuring00:34 Patient privacy, consent, and NHS data00:37 What cancer care could look like in 10 years00:40 Why this work matters personallySend us Fan MailTo learn more about Bryden Wood's Design to Value philosophy, visit www.brydenwood.com. You can also follow Bryden Wood on LinkedIn.












